IPO - Mineralys Therapeutics, Inc.

Form Type: SCHEDULE 13D/A

Filing Date: 2025-03-17

Corporate Action: Ipo

Type: Update

Accession Number: 000141588925008276

Filing Summary: This document is an Amendment No. 2 to the Schedule 13D originally filed on February 24, 2023, with updates reflecting activities as of March 13, 2025. On this date, Samsara LP acquired 600,000 shares of common stock at $13.50 per share, totaling an investment of $8.1 million funded by its working capital. The ownership structure includes 5,674,916 shares directly held by Samsara LP and stock options held by Dr. Akkaraju. The statement further notes that the percentage of share ownership is based on adjusted totals reflecting recent offerings and stock options. Additionally, a lock-up agreement prohibits company executives and directors from transferring securities for 60 days after the recent offering, needing consent from specific financial institutions for any transactions. This filing also incorporates key agreements pertinent to the securities held by the Reporting Persons and details about the total shares outstanding and stock options beneficially owned.

Document Link: View Document

Form Type: 424B5

Filing Date: 2025-03-12

Corporate Action: Ipo

Type: New

Accession Number: 000162828025012332

Filing Summary: Mineralys Therapeutics, Inc. is offering 12,962,962 shares of its common stock at a public offering price of $13.50 per share, targeting proceeds of approximately $174.99 million, with estimated net proceeds of about $164.2 million to fund clinical development of its product candidate, lorundrostat, designed for treating cardiorenal conditions linked to dysregulated aldosterone. The offering is associated with the company's status as an emerging growth company, allowing it to benefit from reduced disclosure requirements under federal laws. Recent data from pivotal clinical trials demonstrate statistically significant efficacy of lorundrostat in reducing blood pressure in patients with uncontrolled and resistant hypertension, highlighting the company's potential in addressing significant market needs. The underwriting group includes notable firms such as BofA Securities, Evercore ISI, and Goldman Sachs, with a 30-day option for underwriters to purchase additional shares. The shares are expected to be available for delivery on March 13, 2025.

Document Link: View Document

Form Type: 8-K

Filing Date: 2025-03-12

Corporate Action: Ipo

Type: New

Accession Number: 000162828025012335

Filing Summary: On March 11, 2025, Mineralys Therapeutics, Inc. entered into an underwriting agreement with BofA Securities, Inc., Evercore Group L.L.C., and Goldman Sachs & Co. LLC for the issuance and sale of 12,962,962 shares of common stock at a public offering price of $13.50 per share. The underwriters will purchase the shares from the company at a price of $12.69 per share. The expected net proceeds from the offering are approximately $164.2 million, or $188.8 million if the underwriters' option to purchase additional shares is fully exercised. The offering is slated to close on March 13, 2025, subject to customary closing conditions. This transaction is part of the company's shelf registration statement on Form S-3, declared effective by the SEC. Additionally, the company issued press releases on March 10 and March 11, 2025, regarding the commencement and pricing of the offering. The Underwriting Agreement contains various standard conditions and indemnification clauses, and references to the complete document and legal opinions are included as part of the filing.

Document Link: View Document